Alnylam gets $2B funding boost from Blackstone to develop drug pipeline
A key component of the deal includes a $1 billion purchase of 50% of royalties owed to Alnylam on sales of inclisiran, a drug for hypercholesterolemia that works by gene silencing. The company's CEO said uncertainty and volatility due to Covid-19 meant the timing was right for the deal.
